Journal of Antimicrobial Chemotherapy
Papers 10,000
1 page of 1,000 pages (10k results)
#1Minh Patrick Lê (University of Paris)H-Index: 6
#2Valentine Marie Ferre (University of Paris)H-Index: 7
Last. G. Peytavin (University of Paris)H-Index: 27
view all 9 authors...
#1Michael T. Osterholm (Center for Infectious Disease Research and Policy)H-Index: 74
The COVID public health emergency has brought home how vulnerable we are to forces beyond our control. We are losing our ability to treat infectious diseases for a number of reasons, including antimicrobial resistance (AMR). AMR is a 'slow-moving' threat, which makes it harder to recognize and address. The situation has not been helped by the difficulty we have had in seeing the actions and health of everyone on this planet as interconnected. The COVID pandemic has changed this. Despite the dire...
#1Tom G. Jacobs (Radboud University Nijmegen)H-Index: 1
#2Catia Marzolini (University Hospital of Basel)H-Index: 31
Last. David M. Burger (Radboud University Nijmegen)H-Index: 73
view all 4 authors...
Global use of dexamethasone in COVID-19 patients has revealed a poor understanding of the drug-drug interaction (DDI) potential of dexamethasone, particularly with antiretroviral agents (ARVs). Dexamethasone is both a substrate and a dose-dependent inducer of cytochrome P450 3A4 (CYP3A4). As many ARVs are substrates and/or inhibitors or inducers of CYP3A4, there is concern about DDIs with dexamethasone either as a perpetrator or a victim. Assessment of DDIs that involve dexamethasone is complex ...
#1Luis Ayerbe (QMUL: Queen Mary University of London)H-Index: 15
#2Carlos Risco-RiscoH-Index: 1
Last. Salma Ayis ('KCL': King's College London)H-Index: 33
view all 5 authors...
Background null Azithromycin has been widely used in the management of COVID-19. However, the evidence on its actual effects remains disperse and difficult to apply in clinical settings. This systematic review and meta-analysis summarizes the available evidence to date on the beneficial and adverse effects of azithromycin in patients with COVID-19. null Methods null The PRISMA 2020 statement criteria were followed. Randomized controlled trials (RCTs) and observational studies comparing clinical ...
#1Daniel W. Berman (TU: Temple University)H-Index: 4
#2Ruth Neale (TU: Temple University)
Rapid point-of-care tests are needed to control antimicrobial consumption, as recognized by the Longitude Prize. However, in addition to bacterial pathogen identification, clinicians need more information, such as which antimicrobial will be effective and how severe the infection really is. This technology is beginning to emerge, but both economic and technological challenges remain before it can be delivered, especially in low- and middle-income countries. This article outlines these challenges...
#1Kim Dao (UNIL: University of Lausanne)H-Index: 6
#2Aline Fuchs (UNIL: University of Lausanne)H-Index: 8
Last. Monia Guidi (UNIL: University of Lausanne)H-Index: 20
view all 12 authors...
OBJECTIVES Imipenem is a broad-spectrum antibacterial agent used in critically ill neonates after failure of first-line treatments. Few studies have described imipenem disposition in this population. The objectives of our study were: (i) to characterize imipenem population pharmacokinetics (PK) in a cohort of neonates; and (ii) to conduct model-based simulations to evaluate the performance of six different dosing regimens aiming at optimizing PK target attainment. METHODS A total of 173 plasma s...
#1Paula Klauke (Charité)
#2Frank J. Schwab (Charité)H-Index: 94
Last. Friederike Maechler (Charité)H-Index: 11
view all 4 authors...
OBJECTIVES To investigate therapeutical drugs other than antimicrobials as risk factors for the acquisition of ESBL-producing Enterobacterales (ESBL-E). METHODS This matched case-control study is based on rectal surveillance screening data obtained during a larger trial between 2014 and 2016 upon patients' admission and at least once before discharge in eight non-ICU wards. Patients with ward-acquired ESBL-E (cases) were matched 1:1 to non-ESBL-E carriers (controls) based on ward, number of scre...
#1Tanya Laird (Murdoch University)H-Index: 9
#2David Jordan (New South Wales Department of Primary Industries)H-Index: 58
Last. Sam Abraham (Murdoch University)H-Index: 24
view all 9 authors...
BACKGROUND A key component to control of antimicrobial resistance (AMR) is the surveillance of food animals. Currently, national programmes test only limited isolates per animal species per year, an approach tacitly assuming that heterogeneity of AMR across animal populations is negligible. If the latter assumption is incorrect then the risk to humans from AMR in the food chain is underestimated. OBJECTIVES To demonstrate the extent of phenotypic and genetic heterogeneity of Escherichia coli in ...
#1I Marr (Canberra Hospital)
#2K Swe ('JHCH': John Hunter Hospital)
Last. John Ferguson (University of Newcastle)H-Index: 26
view all 6 authors...
Background null CoNS bacteraemia causes significant neonatal morbidity. Previous work has suggested that β-lactam antibiotics vary in their binding affinity to PBP2a (produced by the mecA gene) present in most CoNS. null Objectives null We evaluated cefazolin MICs for CoNS isolated in an Australian neonatal ICU (NICU) and correlated them with isolate genotype and phenotype. null Methods null Significant blood isolates from 2009 to 2017 were speciated and underwent broth microdilution testing for...
#1Todd T. Brown (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
#2Krista Yuhas (Fred Hutchinson Cancer Research Center)H-Index: 1
Last. Timothy J. Wilkin (Cornell University)H-Index: 26
view all 12 authors...
BACKGROUND Tenofovir disoproxil fumarate-containing pre-exposure prophylaxis (PrEP) has been associated with decreases in bone mineral density (BMD), but the bone effects of other non-tenofovir disoproxil fumarate candidate PrEP regimens are not well described. METHODS The HPTN 069/ACTG A5305 study randomized 406 US cisgender men and transgender women, and 188 cisgender women at risk for HIV infection to one of four double-blinded regimens: (i) maraviroc; (ii) maraviroc + emtricitabine; (iii) ma...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.